The Amedica Corporation recently released the results of its 24-month level 1 trial for the CASCADE composite silicon nitride fusion device...
Read More
CRE treatment to be developed, sold by Allergan, AstraZeneca
Allergan plc and AstraZeneca ink a global agreement to develop and commercialize ATM-AVI, an investigational fixed-dosed combination antibiotic, aztreonam and avibactam, for the treatment of serious infections caused by metallo-beta-lactamase (MBL)-producing Gram-negative bacteria, a difficult-to-treat subtype of carbapenem-resistant Enterobacteriaceae for which there are limited treatment options.
Read MoreGet DrBond
Stop Procrastinating. Start Bonding! Get the App on your phone to bond with the medical world, while on the go!
